Identification of a predictive phosphoproteomic signature of response to atezolizumab and bevacizumab (AB) in patients with advanced hepatocellular carcinoma (aHCC)

被引：0
|
作者：
Sarker, Debashis
Borek, Weronika E.
Pedicona, Federico
Zen, Yoh
Christopher, Josie A.
Karampera, Christina
Campbell, Amy
Khorsandi, Shirin Elizabeth
Dowe, Thomas
Habarwaa, Marwo
Britton, David James
Heaton, Nigel
Cutillas, Pedro Rodriguez
Williamson, Andrew
Dokal, Arran David
机构：
[1] Kings Coll Hosp London, Inst Liver Studies, London, England
[2] Kinomica Ltd, Macclesfield, Cheshire, England
[3] Kings Coll Hosp London, London, England
[4] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2631
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma
    Song, Byeong Geun
    Goh, Myung Ji
    Kang, Wonseok
    Sinn, Dong Hyun
    Gwak, Geum-Youn
    Choi, Moon Seok
    Lee, Joon Hyeok
    Paik, Yong-Han
    GUT AND LIVER, 2024, 18 (04) : 709 - 718
  • [42] Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tada, Toshifumi
    Kumada, Takashi
    Hiraoka, Atsushi
    Kariyama, Kazuya
    Tani, Joji
    Hirooka, Masashi
    Takaguchi, Koichi
    Atsukawa, Masanori
    Fukunishi, Shinya
    Itobayashi, Ei
    Tsuji, Kunihiko
    Tajiri, Kazuto
    Ochi, Hironori
    Ishikawa, Toru
    Yasuda, Satoshi
    Ogawa, Chikara
    Toyoda, Hidenori
    Hatanaka, Takeshi
    Nishimura, Takashi
    Kakizaki, Satoru
    Kawata, Kazuhito
    Shimada, Noritomo
    Tada, Fujimasa
    Nouso, Kazuhiro
    Tsutsui, Akemi
    Ohama, Hideko
    Morishita, Asahiro
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Kosaka, Hisashi
    Imai, Michitaka
    Naganuma, Atsushi
    Nakamura, Shinichiro
    Koizumi, Yohei
    Matono, Tomomitsu
    Kaibori, Masaki
    Iijima, Hiroko
    Hiasa, Yoichi
    ONCOLOGY, 2023, 101 (04) : 270 - 281
  • [43] Considering nutritional status to improve outcomes of patients treated by atezolizumab-bevacizumab for advanced hepatocellular carcinoma
    Allaire, Manon
    Avila, Matias A.
    LIVER INTERNATIONAL, 2024, 44 (06) : 1276 - 1277
  • [44] FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
    Casak, Sandra J.
    Donoghue, Martha
    Fashoyin-Aje, Lola
    Jiang, Xiaoping
    Rodriguez, Lisa
    Shen, Yuan-Li
    Xu, Yuan
    Jiang, Xiling
    Liu, Jiang
    Zhao, Hong
    Pierce, William F.
    Mehta, Shubhangi
    Goldberg, Kirsten B.
    Theoret, Marc R.
    Kluetz, Paul G.
    Pazdur, Richard
    Lemery, Steven J.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1836 - 1841
  • [45] TARGETED THERAPY ADAPTED TO TUMOR BIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA OR HEPATOCHOLANGIOCARCINOMA REFRACTORY TO ATEZOLIZUMAB/BEVACIZUMAB
    Limousin, Wendy
    Laurent-Puig, Pierre
    Ziol, Marianne
    Ganne-Carrie, Nathalie
    Nahon, Pierre
    Ait-Omar, Amal
    Seror, Olivier
    Sidali, Sabrina
    Campani, Claudia
    Blanc, Pierre
    Lermine, Alban
    Marisa, Laetitia
    Zucman-Rossi, Jessica
    Nault, Jean-Charles
    HEPATOLOGY, 2023, 78 : S203 - S204
  • [46] Efficacy and safety of atezolizumab and bevacizumab in the realworld treatment of Child Pugh B patients with advanced hepatocellular carcinoma
    Stella, Leonardo
    Ponziani, Francesca
    Santopaolo, Francesco
    Hollande, Clemence
    Gasbarrini, Antonio
    Sidali, Sabrina
    Pompili, Maurizio
    Bouattour, Mohamed
    JOURNAL OF HEPATOLOGY, 2023, 78 : S578 - S579
  • [47] TREATMENT PATTERNS IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC) PATIENTS IN SPAIN.
    Polanco Sanchez, C.
    Suarez Rodriguez, J.
    Jaffe, D.
    DeCongelio, M.
    Dubell, A.
    Moreno, M. E.
    VALUE IN HEALTH, 2019, 22 : S500 - S500
  • [48] Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma
    Ollivier-Hourmand, Isabelle
    Allaire, Manon
    Cervoni, Jean Paul
    JOURNAL OF HEPATOLOGY, 2022, 77 (02)
  • [49] Clinical Parameters Work Well as Predictive Factors for Atezolizumab and Bevacizumab Treatment in Hepatocellular Carcinoma
    Lee, Ji Yeon
    Sung, Pil Soo
    GUT AND LIVER, 2024, 18 (04) : 558 - 559
  • [50] Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
    Vithayathil, Mathew
    D'Alessio, Antonio
    Fulgenzi, Claudia A. M.
    Nishida, Naoshi
    Schoenlein, Martin
    von Felden, Johann
    Schulze, Kornelius
    Wege, Henning
    Saeed, Anwaar
    Wietharn, Brooke
    Hildebrand, Hannah
    Wu, Linda
    Ang, Celina
    Marron, Thomas U.
    Weinmann, Arndt
    Galle, Peter R.
    Bettinger, Dominik
    Bengsch, Bertram
    Vogel, Arndt
    Balcar, Lorenz
    Scheiner, Bernhard
    Lee, Pei-Chang
    Huang, Yi-Hsiang
    Amara, Suneetha
    Muzaffar, Mahvish
    Naqash, Abdul Rafeh
    Cammarota, Antonella
    Personeni, Nicola
    Pressiani, Tiziana
    Pinter, Matthias
    Cortellini, Alessio
    Kudo, Masatoshi
    Rimassa, Lorenza
    Pinato, David J.
    Sharma, Rohini
    LIVER INTERNATIONAL, 2022, 42 (11) : 2538 - 2547
12345